BETA
Your AI-Trained Oncology Knowledge Connection!
Stacey Cohen, MD, presents the case of a 39-year-old woman with high-risk stage II colorectal cancer, highlighting how ctDNA helped inform treatment selection.
Stay up to date on recent advances in the multidisciplinary approach to cancer.
Preoperative Counseling Increases Shared Decision-Making in CRC Surgery
Counseling received prior to colorectal surgery using 3-dimensional–printed anatomic models reduced mean anxiety scores vs conventional counseling.
Sotorasib Combo Approval May Address Novel Therapy Need in KRAS G12C+ CRC
The approval of sotorasib plus panitumumab is a “welcome step” in KRAS G12C-mutated colorectal cancer, according to Marwan G. Fakih, MD.
Genomic Alterations May Cause Resistance to Sotorasib KRAS G12C+ CRC Combo
Emergent alteration patterns were similarly diverse across treatment arms in the phase 3 CodeBreaK 300 study.
Optimizing Metastatic CRC Outcomes Following Fruquintinib Approval
Oncology pharmacist Jagoda Misniakiewicz, PharmD, discusses the potential efficacy and safety profile of fruquintinib in patients with metastatic CRC.
Anlotinib Shows Noninferiority to Bevacizumab in RAS/BRAF Wild-Type mCRC
Anlotinib/chemotherapy showed comparable efficacy vs bevacizumab/chemotherapy in patients with RAS/BRAF wild-type metastatic colorectal cancer.
PFS Improves in BRAF V600E+ CRC With Encorafenib Combo
Updated findings from BREAKWATER support encorafenib plus cetuximab and chemotherapy as a new standard of care in BRAF V600E-mutated metastatic CRC.